The Pharma Data

JANUARY 10, 2021

Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. In July 2020, the U.S.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Supply Trials 52

The Pharma Data

NOVEMBER 22, 2020

Molecular Partners two antiviral DARPin® candidates, MP0420 and MP0423, are designed to target multiple different sites on the SARS-CoV-2 virus simultaneously for enhanced antiviral effects and potential use as both prophylactics and treatments. million doses of MP0420, if it is approved in Switzerland.

Trials 40

Trials Clinical Trials Licensing Licensing 40

The Pharma Data

NOVEMBER 18, 2020

These restrictions and uncertainty around the duration, severity and geographic scope of the COVID-19 outbreak are projected to slow down the enrolment of patients due to re-prioritisation of hospital activities towards COVID-19 patients and away from clinical studies such as PARADIGME.

Trials 40

Trials Clinical Supply Production Therapies 40

The Pharma Data

AUGUST 15, 2021

Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease.

Disease 52

Disease FDA Treatment Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and treatment of COVID-19, with the possibility to manufacture at scale, easy administration and with the potential to bypass cold storage. During the clinical development stage, Molecular Partners will provide clinical supply.

Therapies 40

Therapies Virus Treatment Clinical Trials 40

The Pharma Data

DECEMBER 4, 2021

The companies are exploring these advances through their newly created Pfizer Amazon Collaboration Team (PACT) initiative, which applies AWS capabilities in analytics, machine learning, compute, storage, security, and cloud data warehousing to Pfizer laboratory, clinical manufacturing and clinical supply chain efforts.

Drug Development 52

Drug Development Small Molecule Synthetic Chemistry Drugs 52

The Pharma Data

JANUARY 24, 2021

Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. Food and Drug Administration (“FDA”) approval.

FDA 52

FDA Drugs Clinical Development Disease 52

Fierce BioTech

FEBRUARY 6, 2025

Discover key qualities to look for to bring treatments to market faster and improve patient outcomes. Discover key qualities to look for to bring treatments to market faster and improve patient outcomes. Discover key qualities to look for to bring treatments to market faster and improve patient outcomes. Download now.

Clinical Supply 52

Clinical Supply Drug Development Treatment Marketing 52

PPD

FEBRUARY 3, 2025

In todays clinical research landscape, it is both essential and challenging to accelerate clinical trials. Speeding up timelines reduces costs, maximizes ROI and ensures that patients receive the treatments they need without unnecessary delays. Delays in clinical trials can have significant financial consequences for sponsors.

Clinical Trials 52

Clinical Trials Trials Clinical Supply Drug Development 52